GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (FRA:HN30) » Definitions » Cyclically Adjusted Price-to-FCF

Restart Life Sciences (FRA:HN30) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Restart Life Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Restart Life Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Restart Life Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences Cyclically Adjusted Price-to-FCF Chart

Restart Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Restart Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Restart Life Sciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Restart Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Restart Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Cyclically Adjusted Price-to-FCF falls into.


;
;

Restart Life Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Restart Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Restart Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.006/129.1809*129.1809
=-0.006

Current CPI (Mar. 2025) = 129.1809.

Restart Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.027 100.500 -0.035
201509 -0.117 100.421 -0.151
201512 -0.187 99.947 -0.242
201603 -0.040 101.054 -0.051
201606 0.000 102.002 0.000
201609 -0.147 101.765 -0.187
201612 -0.169 101.449 -0.215
201703 -0.074 102.634 -0.093
201706 -0.127 103.029 -0.159
201709 -0.076 103.345 -0.095
201712 -0.173 103.345 -0.216
201803 -0.117 105.004 -0.144
201806 -0.022 105.557 -0.027
201809 -0.041 105.636 -0.050
201812 -0.126 105.399 -0.154
201903 -0.054 106.979 -0.065
201906 -0.047 107.690 -0.056
201909 -0.049 107.611 -0.059
201912 -0.035 107.769 -0.042
202003 -0.038 107.927 -0.045
202006 -0.020 108.401 -0.024
202009 -0.015 108.164 -0.018
202012 -0.024 108.559 -0.029
202103 -0.038 110.298 -0.045
202106 -0.024 111.720 -0.028
202109 -0.023 112.905 -0.026
202112 -0.034 113.774 -0.039
202203 -0.035 117.646 -0.038
202206 -0.026 120.806 -0.028
202209 -0.009 120.648 -0.010
202212 -0.010 120.964 -0.011
202303 -0.008 122.702 -0.008
202306 -0.005 124.203 -0.005
202309 0.000 125.230 0.000
202312 -0.001 125.072 -0.001
202403 -0.002 126.258 -0.002
202406 0.000 127.522 0.000
202409 0.000 127.285 0.000
202412 0.000 127.364 0.000
202503 -0.006 129.181 -0.006

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Restart Life Sciences  (FRA:HN30) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Restart Life Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Restart Life Sciences Business Description

Traded in Other Exchanges
Address
700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. Its focus is on creating health foods that address the needs of this community. Its flagship developments include natural remedies for individuals on the Autism Spectrum, Specialty Health Foods, Psilocybin Clinical Trial for Fragile X Syndrome, and Orphan Drug Designation (FDA and EMA). The company operates in one industry segment, being research and development of psilocybin, and in one geographic area, being Canada.

Restart Life Sciences Headlines

No Headlines